Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of CSF-1 Receptor, in Subjects With Moderately to Severely Active Crohn's

NCT03854305 is registered in ClinicalTrials.gov with Provention Bio, Inc. as lead sponsor.

NCT NCT03854305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03854305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of CSF-1 Receptor, in Subjects With Moderately to Severely Active Crohn's
Lead sponsor
Provention Bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2018
Completion date
August 13, 2019
Enrollment
93 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease